

## 8. Literaturverzeichnis

Achiron A, and Barak Y

Multiple Sclerosis-From Probable to Definite Diagnosis: A 7-Year Prospective Study

Arch Neurol 2000; 57:974-979

Amato MP, Ponziani G

A prospective study on the prognosis of multiple sclerosis

Neurol Sci 2000; 21:831-838

Anderson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Frederikson S, Gallo P, Grimaldi LM, Gronning M, Keir G, Lamers K, Link H, Magalhaes A, Massaro AR, Öhman S, Reiber H, Rönnbäck L, Schlupe M, Schuller E, Sindic CJM, Thompson EJ, Trojano M, Wurster U

Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report

J Neurol Neurosurg Psychiatry 1994; 57:897-902

Avasarala JR, Cross AH, Trotter JL

Oligoclonal Band Number as a Marker for Prognosis in multiple sclerosis

Arch Neurol 2001; 58:2044-2045

Bakshi R, Hutton GJ, Miller JR, Radue EW

The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis

Neurology 2004; 63:3-11

Banwell BL

Pediatric multiple sclerosis

Curr Neurol Neurosci Rep 2004; 4:245-252

Barkhof F, Brück W, De Groot CJ, Bergers E, Hulshof S, Geurts J, Polman CH, van der Valk P

Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance

Arch Neurol 2003; 60:1073-1081

Bartosik-Psujek H, Archelos JJ

Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG

J Neurol 2004; 251:414-420

Baum K, Nehring C, Schörner W, Girke W

Relations between MRI and CT findings, cerebrospinal fluid parameters and clinical features

Clin Neurol Neurosurg 1990; 92:49-55

Beer S, Rosler KM, Hess CW

Diagnostic value of paraclinical tests in multiple sclerosis: relative sensitivities and specificities for reclassification according to the Poser committee criteria

J Neurol Neurosurg Psychiatry 1995; 59:152-159

Bergamaschi R, Tonietti S, Franciotta E, Candeloro E, Tavazzi E, Piccolo G, Romani A, Cosi V  
Oligoclonal bands in Devic's Neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examination  
Multiple Sclerosis 2004; 10:2-4

Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M  
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event  
N Engl J Med 2003; 349:139-145

Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri P B, Capobianco M, Milano E, Melis F, Giordana MT  
Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory  
J Neurol Neurosurg Psychiatry 2002; 73:148-153

Bourahoui A, de Seze J, Gutierrez R, Onraed B, Hennache B, Ferriby D, Stojkovic T, Vermersch P  
CSF isoelectrofocusing in a large cohort of MS and other neurological diseases  
European Journal of Neurology 2004; 11:525-529

Boutin B, Esquivel E, Mayer M, Chaumet S, Ponsot G, Arthuis M  
Multiple sclerosis in children: report of clinical and paraclinical features of 19 cases  
Neuropediatrics 1988; 19:118-123

Brass SD, Sridar Narayanan, Antel JP, Lapierre Y, Collins L, Arnold LD  
Axonal Damage in Multiple Sclerosis Patients with High versus Low Expanded Disability Status Scale Score  
Can J Neurol Sci 2004; 31:225-228

Brück W, Stadelmann C  
Inflammation and degeneration in multiple sclerosis  
Neurol Sci 2003; 24:265-267

Caroscio JT, Kochwa S, Sacks H, Makuku S, Cohen JA, Yahr MD  
Quantitative cerebrospinal fluid IgG measurements as a marker of disease activity in multiple sclerosis  
Arch Neurol 1986; 43:1129-1131

Cepok S, Zhou D, Srivastava R, Nessler S, Stei S, Büssow K, Sommer N, Hemmer B  
Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis  
J Clin Invest 2005; 115:1352-1360

Cohen BA, Mikol DD  
Mitoxantrone treatment of multiple sclerosis: Safety considerations  
Neurology 2004; 63:28-32

- Cole SR, Beck RW, Moke PS, Kaufman DI, Tourtellotte WW  
The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group  
Neurology 1998; 51: 885 – 887
- Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, Hartung HP, Seeldrayers P, Soelberg Sørensen P, Rovaris M, Martinelli V, Hommes OR, and the Early Treatment of Multiple Sclerosis Study Group  
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study  
Lancet 2001; 357:1576–1582
- Comi G  
From inflammation to degeneration: the lessons of clinical trials  
Neurol Sci 2003; 24:295–297
- Confavreux C, Claudie C, Touraine F, Ventre JJ, Aimard G, Devic M  
Plasma cells in cerebrospinal fluid and multiple sclerosis: diagnostic yield and clinicobiological correlations  
Acta Neurol Scand 1986; 74:432-438
- Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G  
Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study  
Neurology 1996; 46:1607-1612
- Confavreux C, Vukusic S  
Natural history of multiple sclerosis: implications for counselling and therapy  
Curr Opin Neurol 2002; 15:257-266
- Confavreux C, Vukusic S, Adeleine P  
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process  
Brain 2003; 126:770-782
- O'Connor KC, Bar-Or A, Hafler DA  
The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis  
J Clin Immunol 2001; 21:81-92
- O'Connor P  
The effects of intramuscular interferon beta-1a in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS  
Clin Ther 2003; 25:2865-2874
- Correale J, de los Milagros Bassani Molinas M  
Oligoclonal bands and antibody response in multiple sclerosis  
J Neurol 2002; 249:375-389

- Cross AH, Trotter JL, Lyons JA  
B cells and antibodies in CNS demyelinating disease  
J Neuroimmunol 2001; 112:1–14
- Dalton CM, Brex PA, Miszkiel KA, Hickman SJ, MacManus DG, Plant GT, Thompson AJ, Miller DH  
Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis  
Ann Neurol 2002; 52:47-53
- Davies G, Keir G, Thompson EJ  
The significance of an intrathecal monoclonal immunoglobulin band: a follow-up study  
Neurology 2003; 60:1163-1166
- Derfuss T, Gurkov R, Bergh FT, Goebels N, Hartmann M, Barz C, Wilske B, Autenrieth I, Wick M, Hohlfeld R, Meinl E  
Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response  
Brain 2001; 124:1325–1335
- De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL  
Chemical pathology of acute demyelinating lesions and its correlation with disability  
Ann Neurol 1995; 38:901-909
- Dong-Si T, Weber J, Liu YB, Buhmann C, Bauer H, Bendl C, Schnitzler P, Grond-Ginsbach C, Grau AJ  
Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis  
J Neurol 2004; 251:542-547
- Dyment DA, Ebers GC, Sadovnick AD  
Genetics of multiple sclerosis  
The Lancet Neurology 2004; 3:104-110
- Fainardi E, Castellazzi M, Casetta I, Cultrera R, Vaghi L, Granieri E, Contini C  
Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms  
J Neurol Sci 2004; 217:181-188
- Fangerau T, Schimrigk S, Haupts M, Kaeder M, Ahle G, Brune N, Klinkenberg K, Kotterba S, Mohring M, Sindern E; Multiple Sclerosis Study Group  
Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria.  
Acta Neurol Scand 2004; 109:385-389
- Farrell MA, Kaufmann JC, Gilbert JJ, Noseworthy JH, Armstrong HA, Ebers GC  
Oligoclonal bands in multiple sclerosis: clinical- pathologic correlation  
Neurology 1985; 35:212-218

Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B

Randomised placebo-controlled trial of monthly intravenous immunoglobulin in relapsing-remitting multiple sclerosis

Lancet 1997; 349:589-593

Filipini G, Comi GC, Cosi V, Beviacqua L, Ferrarini M, Martinelli V, Bergamaschi R, Filippi M, Citterio A, D'Incerti L, Campi A, Sberna M, Riti F, Avanzini G, Colombo N, Zappoli F, Scotti G, Savoiaro M

Sensitivities and predictive values of paraclinical tests for diagnosing multiple sclerosis

J Neurol 1994; 241:132-137

Filippi M, Miller DH

Magnetic resonance imaging in the differential diagnosis and monitoring of the treatment of multiple sclerosis

Curr Op Neurol 1996; 9:178-184

Filippi M, Rocca MA, Comi G

The use of quantitative magnetic-resonancebased techniques to monitor the evolution of multiple sclerosis

Lancet Neurology 2003; 2:337-346

Franciotta D, Piccolo G, Guccia M, Bergamaschi R, Zardini E, Melzi d'Eril GV, Dondi E, Cosi V

Lack of both spinal fluid oligoclonal bands and complement 4A protein in an MS patient

Acta Neurol Scand 1994; 89:72-74

Fukazawa T, Kikuchi S, Sasaki H, Hamada K, Hamada T, Miyasaka K, Tashiro K

The significance of oligoclonal bands in multiple sclerosis in Japan: Relevance of immunogenetic backgrounds

J Neuro Sci 1998; 158:209-214

Fukazawa T, Yanagawa T, Kikuchi S, Yabe I, Sasaki H, Hamada T, Miyasaka K, Gomi K, Tashiro K

CTLA-4 gene polymorphism may modulate disease in Japanese multiple sclerosis patients. J

Neurol Sci 1999; 171: 49-55

Gadoth N

Multiple sclerosis in children

Brain Dev 2003; Jun, 25:229-232

Genain CP, Canella B, Hauser SL, Raine CS

Identification of autoantibodies associated with myelin damage in multiple sclerosis

Nature Med 1999; 5:170-175

Ghalie R, Edan G, Laurent M, Mauch E, Eisenman S, Hartung HP, Gonsette RE, Butine MD, Goodkin DE

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS

Neurology 2002; 59:909-913

Ghezzi A, Deplano V, Faroni J, Grasso MG, Liguori M, Marrosu G, Pozzilli C, Simone IL, Zaffaroni M

Multiple sclerosis in childhood: clinical features of 149 cases  
Mult Scler 1997; Feb, 3:43-46

Ghezzi A, Martinelli V, Torri V, Zaffaroni M, Rodegher M, Comi G, Zibetti A, Canal N  
Long term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests  
J Neurol 1999; 246:770-775

Gieffers J, Pohl D, Treib J, Dittmann R, Stephan C, Klotz K, Hanefeld F, Solbach W, Haass A, Maass M

Presence of Chlamydia pneumoniae DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis  
Ann Neurol. 2001; 49:585-589

Giovannoni G, Bever CT

Patients with clinically isolated syndromes suggestive of MS Does MRI allow earlier diagnosis?  
Neurology 2003; 60: 6-7

Goffette S, Schlupe M, Henry H, Duprez T, Sindic CJM

Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis  
J Neurol Neurosurg Psychiatry 2004; 75:308-310

Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S

Disease modifying therapies in multiple sclerosis, Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines  
Neurology 2002; 58:169-178

Hafler DA

Multiple sclerosis  
J Clin Invest 2004; 113:788-794

Hanefeld F, Bauer HJ, Christen HJ, Kruse B, Bruhn H, Frahm J

Multiple sclerosis in childhood: report of 15 cases  
Brain Dev 1991; 13:410-416

Hanefeld F

Multiple sclerosis in childhood  
Curr Opin Neurol Neurosurg 1992; 5:359-363

Hawkins SA, McDonnell GV

Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors  
J Neurol Neurosurg Psychiatry 1999; 67:148-152

Hein T, Hopfenmüller W

Hochrechnung der Zahl an Multiple Sklerose erkrankten Patienten in Deutschland  
Nervenarzt 2000; 71:288-294

Hemmer B, Cepok S, Nessler S, Sommer N

Pathogenesis of multiple sclerosis: an update on immunology  
Curr Opin Neurol 2002; 15:227-231

Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H

The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis  
J Neuroimmunol 2000; 107:161-166

Izquierdo G, Angulo S, Garcia-Moreno JM, Gamero MA, Navarro G,  
Gata JM, Ruiz-Pena JL, Paramo MD

Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients  
Acta Neurol Scand 2002; 105:158-163

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS,  
Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J,  
Brownschidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer  
FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The  
Multiple Sclerosis Collaborative Research Group (MSCRG)  
Ann Neurol 1996; 39:285-294

Jongen PJH, Lamers KJB, Doesburg WH, Lemmens WAJG, Hommes OR

Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary  
progressive multiple sclerosis  
J Neurol Neurosurg Psychiatry 1997;63:446-451

Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttman CR,  
Weiner HL, Gasperini C, Filippi M

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes  
in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis  
Group  
Lancet 1999; 353:964-969

Keegan BM, Noseworthy JH

Multiple sclerosis.  
Ann Rev Med 2002; 53:285-302

Kesselring J

Multiple Sklerose

Baumgartner G, Brandt T, Cohen R, Grüssner O-J, Helmchen H, Schmidt L, (Hrsg.)  
Kohlhammer, Stuttgart 1997

Kleine TO, Zwerenz P, Graser C, Zöfel P

Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic  
inflammation indices and TNF- $\alpha$ , IL-1 $\beta$ , IL-6, IL-8  
Brain Research Bulletin 2003; 61:327-346

- Kornek B, Lassmann H  
Neuropathology of multiple sclerosis-new concepts  
Brain Research Bulletin 2003; 61:321–326
- Kurtzke JF  
Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS)  
Neurology 1983; 33:1444-1452
- Lassmann H, Brück W, Lucchinetti C  
Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.  
Trends Mol Med 2001; 7:115–21
- Lassmann H, Reindl M, Rauschka H, Berger J, Aboul-Enein F, Berger T, Zurbriggen A, Lutterotti A, Brück W, Weber JR, Ullrich R, Schmidbauer M, Jellinger K, Vandeveld M.  
A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions.  
Brain 2003; 126:1347-1357
- Lee KH, Hashimoto SA, Hooge JP, LF Kastrukoff, JJ Oger, DK Li, Paty DW  
Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT  
Neurology 1991; 41:657-660
- Link H, Tibbling G  
Principles of albumin and IgG analysis in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis  
Scand J Clin Lab Invest 1977; 37:397-401
- Lolli F, Halawa I, Link H  
Intrathecal IgG synthesis in multiple sclerosis : comparison between isoelectric focusing and quantitative estimation of cerebrospinal fluid IgG  
J Neurol 1981; 224:159-169
- Lublin FD, Reingold SC  
Defining the clinical course of multiple sclerosis: results of an international survey  
Neurology 1996; 46:907-911
- Lucchinetti CF, Brück W, Rodriguez M, Lassmann H  
Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis  
Brain Pathol 1996; 6:259-274
- Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H  
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination  
Ann Neurol 2000; 47:707-717
- Lunding J, Midgard R, Vedeler CA  
Oligoclonal bands in cerebrospinal fluid: a comparative study of isoelectric focusing, agarose gel electrophoresis and IgG index  
Acta Neurol Scand 2000; 102:322-325



- Lycke JN, Karlsson JE, Andersen O, Rosengren LE  
Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis  
J Neurol Neurosurg Psychiatry 1998; 64:402-404
- Mandler RN, Davies LE, Jeffery DR, Kornfeld M  
Devic's neuromyelitis optica: a clinicopathological study of 8 patients  
Ann Neurol 1993; 34:162-168
- Martinez-Yélamos A, Saiz A, Sanchez-Valle A, Casado RV, Ramon JM, Graus F, Arbizu T  
14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis  
Neurology 2001; 57:722-724
- Martinez-Yelamos Antonio, Albert Saiz, Jordi Bas, Juan Jose Hernandez, Francesc Graus, Txomin Arbizu  
Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis  
Neuroscience Letters 2004; 363:14-17
- Mata S, Lolli F, Soderstrom M, Pinto F, and Link H  
Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a  
Multiple Sclerosis 1999; 5:379-388
- McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS  
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of Multiple Sclerosis  
Ann Neurol 2001; 50:121-127
- McLean BN, Luxton RW, Thompson EJ  
A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the log IgG-index  
Brain 1990; 113:1269-1289
- Mesaros S, Drulovic J, Levic Z  
Clinical characteristics and neurophysiological findings in patients with multiple sclerosis without oligoclonal IgG in cerebrospinal fluid  
Srp Arh Celok Lek 2003; 131:122-126
- Miller JR  
The Importance of Early Diagnosis of Multiple Sclerosis  
J Manag Care Pharm 2004; 10(Suppl 2):4-11
- Mohr DC, Hart SL, Julian L, Cox D, Pelletier D  
Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis  
BMJ 2004; 3:1-5

- Moller JR, Johnson D, Brady RO, Tourtellotte WW, Quarles RH  
Antibodies to myelin-associated glycoprotein (MAG) in the cerebrospinal fluid of multiple sclerosis patients  
J Neuroimmunol 1989; 22:55–61
- Multiple Sklerose-Therapie-Konsensus-Gruppe (MSTKG)  
Immunmodulatorische Stufentherapie der multiplen Sklerose  
Nervenarzt 2001; 72:150-157
- Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG  
Multiple sclerosis  
N Engl J Med 2000; 343:938-952
- Olsson JE, Link H, Muller R  
Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: disability, duration and age of onset  
J Neurol Sci 1976; 27:233-45
- O’Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DPE, Thompson EJ, McDonald WI, Miller DH  
Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica  
J Neurol Neurosurg Psychiatry 1996; 60:382-387
- O’Riordan JI, Thompson AJ, Kingsley DPE, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH  
The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up  
Brain 1998; 121:495–503
- Paolino E, Fainardi E, Ruppi P, Tola MR, Casetta I, Monetti VC, Granieri E, Carreras M  
A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis  
J Neurol Neurosurg Psychiatry 1996; 60:572-575
- Perini P, Calabrese M, Biasi G, Gallo P  
The clinical impact of interferon beta antibodies in relapsing-remitting MS  
J Neurol 2004; 251:305–309
- Pinhas-Hamiel O, Sarova-Pinhas I, Achiron A  
Multiple sclerosis in childhood and adolescence: clinical features and management  
Paediatr Drugs 2001; 3:329-336
- Pirttilä T, Nurmikko T  
CSF oligoclonal bands, MRI, and the diagnosis of multiple sclerosis  
Acta Neurol Scand 1995; 92:468-471

Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weinshenker BG, Noseworthy J, and Rodriguez M,  
Clinical Implications of Benign Multiple Sclerosis: A 20-Year Population-Based Follow-up Study  
Ann Neurol 2004; 56:303–306

Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW  
New diagnostic criteria for multiple sclerosis: guideline for research protocols  
Ann Neurol 1983; 13:227-231

Poser CM, Brinar VV  
Diagnostic criteria for multiple sclerosis  
Clin Neurol Neurosurgery 2001; 103:1-11

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group  
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis  
Lancet 1998; 352:1498–1504

Qin Y, Duquette P, Zhang Y, Olek M, Da RR, Richardson J, Antel JP, Talbot P, Cashman NR, Tourtellotte WW, Wekerle H, Van Den Noort S  
Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis  
Lab Invest 2003; 83:1081-1088

Ramsaransing G, Maurits N, Zwanikken C, De Keyser J  
Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review  
Mult Scler 2001; 7:345-347

Reiber H, Felgenhauer K  
Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system  
Clin Chim Acta 1987; 163:319-328

Reiber H  
Untersuchungen des Liquors zur Diagnose neurologischer Erkrankungen  
In: Holzgraefe M, Reiber H, Felgenhauer K (Hrsg.) Labordiagnostik von Erkrankungen des Nervensystems  
Erlangen, Perimed Fachbuch-Verl.-Ges.1988; S. 35-50

Reiber H, Ungefehr S, Jacobi C  
The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis  
Mult Scler 1998; 4:111-117

Riise T, Groning M, Fernandez O, Lauer K, Midgard R, Minderhoud JM, Nyland H, Palffy G, Poser S, Aarli J  
Early prognostic factors for disability in multiple sclerosis, a European multicenter study  
Acta Neurol Scand 1992; 85:212-218

Rossmann H

Neutralizing Antibodies to Multiple Sclerosis Treatments

J Manag Care Pharm 2004; 10(suppl S-b):12-18

Rovaris M, Filippi M

Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis

Curr Opin Neurol 1999; 12:337-344

Runmarker B, Anderson O

Prognostic factors in multiple sclerosis incidence cohort with twenty five years of follow up

Brain 1993; 116:117-134

Sadatipour BT, Greer JM, Pender MP

Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis

Ann Neurol 1998; 44:980-983

Sadovnick A, Ebers G, Dyment D, Risch N and Canadian Collaborative Study Group

Evidence for genetic basis of multiple sclerosis

Lancet 1996; 347:1728-1730

Sastre-Garriga J, Tintore M, Rovira A, Grive E, Pericot I, Comabella M, Thompson AJ, Montalban X

Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings

Mult Scler 2003; 9:39-43

Satoh J, Yukitake M, Kurohara K, Takashima H, Kuroda Y

Detection of the 14-3-3 protein in the cerebrospinal fluid of Japanese multiple sclerosis patients presenting with severe myelitis

J Neurol Sci 2003; 212:11-20

Schröder M

MUSIS 2.0 - Multiple Sclerosis Information System: An easy-to-use-database to improve the care of patients with multiple sclerosis

Mult Scler 1999; 5:299-301

Selcen D, Anlar B, Renda Y

Multiple sclerosis in childhood: report of 16 cases

Eur Neurol 1996; 36:79-84

Sellebjerg F, Christiansen M, Rasmussen LS, Jaliachvili I, Nielsen PM, Fredriksen JL

The cerebrospinal fluid in multiple sclerosis. Quantitative assessment of intrathecal immunoglobulin synthesis by empirical formulae

Eur J Neurol 1996; 3:548-559

- Sellebjerg F, Jensen CV, Christiansen M  
Intrathecal IgG synthesis and autoantibody-secreting cells in multiple sclerosis  
J Neuroimmunol 2000; 108:207–215
- Simone IL, Carrara D, Tortorella C, Liguori M, Lepore V, Pellegrini F, Bellacosa A, Ceccarelli A, Pavone I, Livrea P  
Course and prognosis in early-onset MS: comparison with adult-onset forms  
Neurology 2002; 59:1922-1928
- Sindern E, Haas J, Stark E, Wurster U  
Early onset MS under the age of 16: clinical and paraclinical features  
Acta Neurol Scand 1992; 86:280-284
- Söderström M, Ya-Ping J, Hillert J, Link H  
Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings  
Neurology 1998; 50:708-714
- Söderström M  
Multiple sclerosis: rationale for early treatment  
Neurol Sci 2003; 24:298–300
- Sonnenberg R  
Klinik, Kernspintomographiebefunde und Liquorbefunde bei der Multiplen Sklerose  
Hannover, Med. Hochsch. Diss. 1996
- Soelberg Sorensen P, Ross C, Clemensen KM, Bendzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N and the Danish Multiple Sclerosis Study Group  
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis  
Lancet 2003; 362:1184-1191
- Stendahl-Brodin L, Link H  
Relation of benign course of multiple sclerosis and low-grade humoral immune response in cerebrospinal fluid  
J Neurol Neurosurg Psychiatry 1980; 43:102-105
- Swanborg RH, Whittum-Hudson JA, Hudson AP  
Infectious agents and multiple sclerosis--are Chlamydia pneumoniae and human herpes virus 6 involved?  
J Neuroimmunol 2003; 136:1-8
- Thompson AJ, Hutchinson M, Martin EA, Mansfield M, Whelan A, Feighery C  
Suspected and clinically definite multiple sclerosis: the relationship between CSF immunoglobulins and clinical course  
J Neurol Neurosurg Psychiatry 1985; 48:989-994

- Thompson AJ, Polman C, Miller D, McDonald WI, Brochet B, Filippi M, Montalban X, De Sa J  
Primary progressive multiple sclerosis  
Brain 1997; 120:1085–1096
- Tintore M, Rovira A, Brieva L, et al.  
Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging  
criteria to predict conversion to CDMS  
Mult Scler 2001; 76:359-363
- Tsai JC, Gilden DH  
Chlamydia pneumoniae and multiple sclerosis: no significant association  
Trends Microbiol 2001; 9:152-154
- Villar LM, Masjuan J, González-Porqué P, Plaza J, Sádaba MC, Roldán E, Bootello A, Alvarez-  
Cermeño JC  
Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in multiple  
sclerosis  
Neurology 2002; 59:555-559
- Villar LM, Masjuan J, González-Porqué P, Plaza J, Sádaba MC, Roldán E, Bootello A, Alvarez-  
Cermeño JC  
Intrathecal IgM Synthesis is a prognostic factor in multiple sclerosis  
Ann Neurol 2003; 53:222-226
- Villar LM, Masjuan J, González-Porqué P, Plaza J, Bootello A, Alvarez-Cermeño JC  
Early differential diagnosis of multiple sclerosis using a new oligoclonal banding test  
Arch Neurol 2005; 62:574-577
- Vukusic S, Confavreux C  
Prognostic factors for progression of disability in the secondary progressive phase of multiple  
sclerosis  
J Neurol Sci 2003; 206:135-137
- Walderveen MAA, van Barkhof F, Hommes OR, Polman CH, Tobi H, Frequin STFM, Valk J  
Correlating MRI and clinical disease activity in multiple sclerosis: Relevance of hypointense  
lesions on short-TR/short-TE (T1 weighted) spin-echo images  
Neurology 1995; 45:1684-1690
- Walker RWH, Thompson EJ, McDonald WI  
Cerebrospinal fluid in multiple sclerosis: relationship between immunoglobulins, leucocytes and  
clinical features  
J Neurol 1985; 232:250-259
- Wandinger KP, Lunemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A, Grundstrom  
E, Ehrlich S, Wernecke KD, Volk HD, Zipp F  
TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-  
beta treatment in multiple sclerosis  
Lancet 2003; 361:2036-2043

Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, Ebers GC  
The natural history of multiple sclerosis: a geographically based study I: clinical course and disability  
Brain 1989; 112:133–146

Wurster U  
Elektrophoreseverfahren- Nachweis und Bedeutung von oligoklonalen Banden  
In: Zettl U.K., Lehmitz R., Mix E. (Hrsg.): Klinische Liquordiagnostik  
Berlin-New York, Walter de Gruyter 2003: S. 207-236

Yao Song-Yi, Stratton CW, Mitchell WM, Sriram S  
CSF oligoclonal bands in MS include antibodies against Chlamydomophila antigens  
Neurology 2001; 56:1168–1176

Young IR, Hall AS, Pallis CA, Legg NJ, Bydder GM, Steiner RE  
Nuclear magnetic resonance imaging of the brain in multiple sclerosis  
Lancet 1981; 8255:1063-1066

Zeman A, McLean B, Keir G, Luxton R, Sharief M, Thompson AJ  
The significance of serum oligoclonal bands in neurological diseases  
J Neurol Neurosurg Psychiatry 1993; 56:32-5

Zeman AZ, Kidd D, Mc Lean BN, Kelly MA, Francis DA, Miller DH, Kendall BE, Rudge P, Thompson EJ, McDonald WI  
A study of oligoclonal band negative multiple sclerosis  
J Neurol Neurosurg Psychiatry 1996; 60:27-30